Dolph Lundgren Confirmed Cancer-Free in 2024
The actor achieved a clear health status following a successful treatment plan for a misdiagnosed kidney cancer.
Updated on Sept. 23, 2026 in Cancer
Actor Dolph Lundgren officially declared himself cancer-free in 2024 after years of intensive medical treatment. His recovery followed the discovery of a specific mutation that led to a corrected diagnosis.
Why it matters
Lundgren’s journey underscores the critical importance of seeking secondary oncological opinions when initial treatments fail to produce results. A precise molecular diagnosis allowed for targeted therapy that ultimately proved effective against his condition.
Lundgren underwent surgery in 2020 to remove six tumors, including one in his liver roughly the size of a small lemon. Following targeted therapy, his tumor volume decreased by 20% to 30% within three months, eventually reaching 90% shrinkage by 2022.
The players
Dolph Lundgren
He is a Swedish actor and filmmaker known for his prominent roles in major Hollywood action cinema.
Dr. Alexandra Drakaki
She is an oncologist at UCLA Health who identified the specific mutation in Lundgren’s tumor cells.
UCLA Health
This is a major academic medical center in Los Angeles that provided the specialized oncology care for the actor.
The details
After an initial 2015 diagnosis and surgery, Lundgren’s condition worsened, leading to the removal of six tumors in 2020. A second opinion from Dr. Alexandra Drakaki at UCLA Health revealed that the actor had been misdiagnosed, as his tumor cells actually carried a mutation more commonly associated with lung cancer.
Timeline
Lundgren received his initial kidney cancer diagnosis in 2015.
The actor underwent surgery to remove six tumors in 2020.
Lundgren first spoke publicly about his health in May 2023.
The actor declared that he was cancer-free in 2024.
Lundgren confirmed no evidence of disease in September 2025.
The Big Picture
This case highlights the growing reliance on genomic sequencing within the UCLA Health Jonsson Comprehensive Cancer Center's molecular profiling program. It marks a departure from traditional diagnostic methods, demonstrating how identifying specific mutations can steer patients toward effective targeted therapies.
This story emphasizes the value of obtaining a second opinion from specialized oncology centers if a treatment plan is not yielding expected results. Patients may find that genetic testing for specific mutations can open doors to targeted therapies that were not previously considered.
The takeaway
Advancements in molecular diagnostics are increasingly enabling doctors to reclassify cancers based on genetic markers rather than just original tumor location. This shift often provides a pathway to effective treatment for patients previously considered resistant to standard protocols.
Further reading
Learn more about advancements in precision oncology by visiting the Cancer section.
Source note: This article includes information reported by People.
